COMPASS Pathways plc (FRA:5Y6)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.74B +360.4% |
| Revenue (ttm) | n/a |
| Net Income | -345.03M |
| EPS | -3.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 12.50 |
| Previous Close | 12.00 |
| Day's Range | 12.40 - 12.50 |
| 52-Week Range | 3.72 - 13.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About COMPASS Pathways
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]
News
COMPASS Pathways Transcript: Canaccord Genuity's 46th Annual Growth Conference
COMP360 is advancing toward a Q4 NDA filing, with FDA review and DEA rescheduling expected to enable a first-half 2027 launch. The product offers rapid, durable relief for treatment-resistant depression, with a favorable safety profile and strong payer interest. A late-stage PTSD program is also progressing.
Compass Pathways price target lowered to $65 from $70 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Compass Pathways (CMPS) to $65 from $70 and keeps a Buy rating on the shares. The firm moderated the…
Compass Pathways price target raised to $18 from $17 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Compass Pathways (CMPS) to $18 from $17 and keeps an Overweight rating on the shares.
Psychedelic: Compass Pathways, GH Research report quarterly earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a DSMB approval and a CEO appointment. EARNINGS: On Thursday, GH…
Compass Pathways price target raised to $22 from $17 at B. Riley
B. Riley analyst Madison El-Saadi raised the firm’s price target on Compass Pathways (CMPS) to $22 from $17 and keeps a Buy rating on the shares post the Q2 report.
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways price target lowered to $21 from $22 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Compass Pathways (CMPS) to $21 from $22 and keeps an Outperform rating on the shares. Compass Pathways reported a…
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways files automatic mixed securities shelf
16:06 EDT Compass Pathways (CMPS) files automatic mixed securities shelf
COMPASS Pathways Earnings Call Transcript: Q2 2026
COMP360 achieved positive phase III results in TRD, with NDA submission underway and launch targeted for H1 2027. Strong cash reserves support commercial readiness, and prescriber interest is high, positioning the product for a significant impact in a large, underserved market.
COMPASS Pathways Quarterly report: Q2 2026
COMPASS Pathways has published its Q2 2026 quarterly earnings report on August 5, 2026.
COMPASS Pathways Earnings release: Q2 2026
COMPASS Pathways released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
COMPASS Pathways Slides: Q2 2026
COMPASS Pathways has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Compass Pathways reports Q2 EPS ($1.88), consensus (34c)
Reports Q2 Research and development expenses $29.2M. The net loss was primarily driven by non-cash fair value adjustments related to warrants. The change in fair value was $205.6M loss. “The…
Compass Pathways current cash position sufficient throughout 2028
The company says the current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028. Cash and cash equivalents were $433.3M as of…
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways initiated with an Equal Weight at Wells Fargo
Wells Fargo analyst Benjamin Burnett initiated coverage of Compass Pathways (CMPS) with an Equal Weight rating and $13 price target While the two positive Phase 3 studies should meet the…
COMPASS Pathways PLC put volume heavy and directionally bearish
Bearish flow noted in COMPASS Pathways (CMPS) PLC with 1,774 puts trading, or 3x expected. Most active are Nov-26 10 puts and Jul-26 13 calls, with total volume in those…
Compass Pathways’ COMP360 treatment featured in published PTSD trial
Compass Pathways (CMPS) announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients wi...
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPO...
Evercore upgrades Compass Pathways to Outperform, views approval as likely
As previously reported, Evercore ISI upgraded Compass Pathways (CMPS) to Outperform from In Line with a price target of $21, up from $8. The crux of the firm’s previous downgrade…
COMPASS Pathways Transcript: Study result
COMP360 showed rapid and durable efficacy in highly treatment-resistant depression, with about 40% of patients achieving meaningful response and a favorable safety profile through 26 weeks. Regulatory review is underway, with anticipated U.S. launch in 2027 and strong stakeholder enthusiasm for this differentiated treatment.